Clinically Meaningful Responses to Fremanezumab in Patients with Migraine and Documented Inadequate Response to 2-4 Classes of Migraine Preventive Medications in the Randomized, Placebo-Controlled FOCUS Study

被引：0
|
作者：
Spierings, Egilius L. H. [1 ]
Ning, Xiaoping [2 ]
Galic, Maja [3 ]
Cohen, Joshua M. [2 ]
Yang, Ronghua [2 ]
机构：
[1] Medvadis Res Corp, Watertown, MA USA
[2] Teva Pharmaceut Ind, Frazer, PA USA
[3] Teva Pharmaceut, Amsterdam, Netherlands
来源：
ANNALS OF NEUROLOGY | 2019年 / 86卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
M195
引用
收藏
页码：S168 / S168
页数：1
相关论文
共 50 条
  • [31] Efficacy and safety of fremanezumab in patients with migraine and documented inadequate response to 2-4 classes of migraine preventive treatments: results of the international, multicentre, randomised, placebo-controlled FOCUS study
    Ferrari, Michel D.
    Diener, Hans Christoph
    Ning, Xiaoping
    Galic, Maja
    Cohen, Joshua M.
    Yang, Ronghua
    Ashina, Messoud
    JOURNAL OF HEADACHE AND PAIN, 2020, 21 (SUPPL 1):
  • [32] Early onset of response to fremanezumab in patients with migraine and a documented inadequate response to 2-4 classes of migraine preventive treatments: results of the international, multicentre, randomised, placebo-controlled FOCUS study
    Spierings, Egilius L. H.
    Machkova, Martina
    Ning, Xiaoping
    Galic, Maja
    Cohen, Joshua M.
    Yang, Ronghua
    JOURNAL OF HEADACHE AND PAIN, 2020, 21 (SUPPL 1):
  • [33] Efficacy With Fremanezumab in Migraine Patients With Comorbid Moderate to Severe Depression and Documented Inadequate Response to 2-4 Classes of Migraine Preventive Treatments: Subgroup Analysis of the Randomized, Placebo-controlled FOCUS Study
    Buse, Dawn
    Cohen, Joshua
    Ramirez-Campos, Verena
    Yang, Ronghua
    Ning, Xiaoping
    Galic, Maja
    Lipton, Richard B.
    NEUROLOGY, 2020, 94 (15)
  • [34] Efficacy with Fremanezumab in Migraine Patients with Comorbid Moderate to Severe Depression and Documented Inadequate Response to 2-4 Classes of Migraine Preventive Treatments: Subgroup Analysis of the Randomized, Placebo-Controlled FOCUS Study
    Lipton, Richard B.
    Cohen, Joshua M.
    Campos, Verena Ramirez
    Yang, Ronghua
    Ning, Xiaoping
    Galic, Maja
    Buse, Dawn C.
    ANNALS OF NEUROLOGY, 2020, 88 : S159 - S160
  • [35] Early Onset of Response to Fremanezumab in Migraine Patients With Moderate to Severe Depression and Documented Inadequate Response to 2-4 Classes of Migraine Preventive Treatments: Subgroup Analysis of the Randomized, Placebo-controlled FOCUS Study
    Blumenfeld, Andrew
    Yang, Ronghua
    Cohen, Joshua M.
    Ramirez-Campos, Verena
    Pozo-Rosich, Patricia
    NEUROLOGY, 2020, 94 (15)
  • [36] Effect of fremanezumab on migraine-specific HRQoL and health status in patients with documented inadequate response to 2-4 classes of migraine preventive medications in the international, multicentre, randomised, placebo-controlled FOCUS study
    Mechtler, L.
    Pozo Rosich, P.
    Ning, X.
    Galic, M.
    Cohen, J. M.
    Yang, R.
    EUROPEAN JOURNAL OF NEUROLOGY, 2019, 26 : 803 - 804
  • [37] Reduction in the number of headache hours and days with fremanezumab in patients with migraine and documented inadequate response to 2-4 migraine preventive medications in the international, multicentre, randomised, placebo-controlled FOCUS study
    Karppa, M.
    Ning, X.
    Galic, M.
    Cohen, J. M.
    Yang, R.
    EUROPEAN JOURNAL OF NEUROLOGY, 2019, 26 : 798 - 798
  • [38] Efficacy of Fremanezumab in Patients with Migraine and Documented Inadequate Response to 3 or 4 Migraine Preventive Medication Classes and Medication Overuse in the International, Multicenter, Randomized, Placebo-Controlled FOCUS Study
    Pazdera, Ladislav
    Ning, Xiaoping
    Campos, Verena Ramirez
    Yang, Ronghua
    Carr, Karen
    Cohen, Joshua M.
    ANNALS OF NEUROLOGY, 2020, 88 : S155 - S156
  • [39] Impact of age and sex on efficacy of fremanezumab in patients with migraine and documented inadequate response to 2-4 classes of migraine preventive treatments: results of the international, multicentre, randomised, placebo-controlled FOCUS study
    MaassenVanDenBrink, Antoinette
    Galic, Maja
    Cohen, Joshua M.
    Ning, Xiaoping
    Yang, Ronghua
    Ramirez-Campos, Verena
    JOURNAL OF HEADACHE AND PAIN, 2020, 21 (SUPPL 1):
  • [40] Efficacy with fremanezumab in migraine patients with comorbid moderate to severe depression and documented inadequate response to 2-4 classes of migraine preventive treatments: subgroup analysis of the randomised, placebo-controlled FOCUS study
    Lipton, Richard B.
    Cohen, Joshua M.
    Ramirez-Campos, Verena
    Yang, Ronghua
    Ning, Xiaoping
    Galic, Maja
    Buse, Dawn C.
    CEPHALALGIA, 2019, 39 : 210 - 211
12345